Kura Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 4, 2026, regarding Kura Oncology, Inc. The filing details the results of the company's Annual Meeting of Stockholders held on that date and the subsequent approval of amendments to equity incentive plans.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan approvals rather than financial performance data.
Material Changes and Voting Results
On June 4, 2026, stockholders approved several key proposals at the Annual Meeting. As of the record date (April 6, 2026), there were 88,762,704 shares outstanding, with 69,778,580 shares present or represented by proxy.
- Director Elections: Diane Parks, Mary T. Szela, and Michael J. Vasconcelles, M.D. were elected as Class III directors to serve until the 2029 Annual Meeting.
- Equity Plan Amendments: Stockholders approved the Amended 2014 Equity Incentive Plan, increasing authorized shares by 6,500,000, and the Amended 2015 Employee Stock Purchase Plan (ESPP), increasing authorized shares by 2,500,000.
- Accounting Firm: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
- Executive Compensation: The "Say-on-Pay" advisory vote was approved. Stockholders indicated a preference for annual advisory votes on executive compensation, a frequency the Board has adopted.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors. The primary focus is the successful ratification of corporate governance matters and equity plan expansions.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the newly amended 2014 Plan and ESPP to assess potential future dilution.
- Confirm the tenure of the newly elected Class III directors (Diane Parks, Mary T. Szela, Michael J. Vasconcelles, M.D.) through 2029.
- Review the full text of the Amended 2014 Plan and Amended ESPP (Exhibits 99.1 and 99.2) for specific terms regarding vesting, exercise prices, and eligibility.
- Note that the filing does not disclose financial results; investors should refer to the most recent 10-K or 10-Q for financial metrics.